SEC Form 4

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

					or Sec	tion 30(n)	of the	e Investmen	t Cor	npany Act	of 1940							
1. Name and Address of Reporting Person [*] Shukla Sanjay					2. Issuer Name and Ticker or Trading Symbol <u>aTYR PHARMA INC</u> [LIFE]							(Che	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
JIIUKIA	<u>Sanjay</u>												C Director	r		10% Ow	ner	
(Last)	3. Date of Earliest Transaction (Month/Day/Year)						2	C Officer below)	Officer (give title below)		Other (s below)	pecify						
3545 JOHN HOPKINS COURT, SUITE #250					05/21/2021								President and CEO					
(Street)						4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line)					
SAN DI	EGO C	A	92121									-	Form filed by One Reporting Person					
(City)	(5	State)	(Zip)											Form filed by More than One Reporting Person				
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
1. Title of Security (Instr. 3) 2. Transa Date (Month/D					action 2A. Deemed Execution Date if any (Month/Day/Yea			Code (Instr.				Beneficia Owned F	s Form ally (D) o following (I) (In		Direct I ndirect E tr. 4) (7. Nature of Indirect Beneficial Ownership		
								Code	v	Amount	(A) o (D)	r Price	Reported Transacti (Instr. 3 a	tion(s)			(Instr. 4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	ve Conversion Date Execution Date, T or Exercise (Month/Day/Year) if any C		Code	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)			
				Code	v	(A)	(D)	Date Exercisabl		xpiration ate	Title	Amount or Number of Shares		(Instr. 4)	m(s)			
Employee Stock Option (Right to buy)	\$4.45	05/21/2021		A		207,000		(1)	0	5/21/2025	Common Stock	207,000	\$0.00	207,000	0	D		

Explanation of Responses:

1. The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning June 21, 2021, such that this option will be fully exercisable on May 21, 2025. This option is subject to accelerated vesting upon termination without cause upon change of control of the issuer.

Remarks:

Nancy Denyes, attorney-in-fact 05/25/2021

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.